Fluoxetine: A review of its use in anxiety disorders and mixed anxiety and depression

CNS Drugs

Volumn 14, Issue 1, 2000, Pages 51-80

  Hurst, Miriam ^a   Lamb, Harriet M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; CARBAMAZEPINE; CITALOPRAM; DESIPRAMINE; DIAZEPAM; ENCAINIDE; FLECAINIDE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; MOCLOBEMIDE; NORFLUOXETINE; PAROXETINE; PHENYTOIN; SERTRALINE; TERFENADINE; VINBLASTINE;

AGORAPHOBIA; ANXIETY NEUROSIS; CLINICAL TRIAL; DEPRESSION; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; HEADACHE; HUMAN; INSOMNIA; META ANALYSIS; OBSESSION; PANIC; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; REVIEW; SOCIAL PHOBIA;

EID: 0033859424     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200014010-00005     Document Type: Review

References (189)

1. 1. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994 Jan; 51:8-19
2. 2. Park LT, Jefferson JW, Greist JH. Obsessive-compulsive disorder: treatment options. CNS Drugs 1997 Mar; 7: 187-202
3. 3. Breslau N, Davis GC, Andreski P, et al. Traumatic events and posttraumatic stress disorder in an urban population of young adults. Arch Gen Psychiatry 1991 Mar; 48: 216-22
4. 4. Fichtner CG, Poddig BE, deVito RA. Post-traumatic stress disorder: pathophysiological aspects and pharmacological approaches to treatment. CNS Drugs 1997 Oct; 8: 293-322
5. 5. Tyrer P, Seivewright N, Murphy S, et al. The Nottingham study of neurotic disorder: comparison of drug and psychological treatments. Lancet 1988 Jul 30; 2: 235-40
6. 6. Brown CS, Rakel RE, Wells BG, et al. A practical update on anxiety disorders and their pharmacologic treatment. Arch Intern Med 1991 May; 151: 873-84
7. 7. Zohar J, Westenberg HGM. Anxiety disorders: a review of TCAs and SSRIs. Proceedings of a consensus meeting held in Geneva, Switzerland, Oct 5-6, 1998 (Data on file)
8. 8. den-Boer JA. Psychopharmacology of comorbid obsessive-compulsive disorder and depression. J Clin Psychiatry 1997; 58 Suppl 8: 17-9
9. 9. Van-Ameringen M, Mancini C, Streiner DL. Fluoxetine efficacy in social phobia [see comments]. J Clin Psychiatry 1993 Jan; 54: 27-32
10. 10. Ballenger JC, Davidson JRT, Lecrubier Y, et al. Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 1998; 59 Suppl. 8: 47-54
11. 11. Kent JM, Coplan JD, German JM. Clinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety. Biol Psychiatry 1998 Nov 1; 44: 812-24
12. 12. BenfieldP, Heel RC, Lewis SP. Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986 Dec; 32 (6): 481-508
13. 13. Gram LF. Fluoxetine. N Engl J Med 1994 Nov 17; 331 (20): 1354-61
14. 14. Beasley CM, Masica DN, Potvin JH. Fluoxetine: a review of receptor and functional effects and their clinical implications. Psychopharmacology 1992 May; 107: 1-10
15. 15. Sheline YI, Bardgett ME, Csernansky JG. Correlated reductions in cerebrospinal fluid 5-HIAA and MHPG concentrations after treatment with selective serotonin reuptake inhibitors. J Clin Psychopharmacol 1997 Feb; 17: 11-4
16. 16. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 1994 Mar; 9 Suppl. 1: 19-26
17. 17. Tauscher J, Pirker W, de Zwaan M, et al. In vivo visualization of serotonin transporters in the human brain during fluoxetine treatment. Eur Neuropsychopharmacol 1999 Jan; 9: 177-9
18. 18. Goodwin GM. How do antidepressants affect serotonin receptors? The role of serotonin receptors in the therapeutic and side effect profile of the SSRIs. J Clin Psychiatry 1996; 57 Suppl. 4: 9-13
19. 19. Lucki I. Serotonin receptor specificity in anxiety disorders. J Clin Psychiatry 1996; 57 Suppl. 6: 5-10
20. 20. Fuller RW, Wong DT, Robertson DW. Fluoxetine, a selective inhibitor of serotonin uptake. Med Res Rev 1991 Jan; 11: 017-34
21. 1A Receptor function in normal subjects on clinical doses of fluoxetine: blunted temperature and hormone responses to ipsapirone challenge. Neuropsychopharmacology 1999 Jun; 20: 628-39
22. 1A-receptor agonist-induced corticotropin and cortisol responses after long term ipsapirone and fluoxetine administration to healthy subjects. Clin Pharmacol Ther 1998 Apr; 63: 428-36
23. 23. Azari NP, Pietrini P, Horwitz B, et al. Individual differences in cerebral metabolic patterns during pharmacotherapy in obsessive-compulsive disorder: a multiple regression/discriminant analysis of positron emission tomographic data. Biol Psychiatry 1993 Dec 1; 34: 798-809
24. 24. Molina V, Montz R, Pérez-Castejón MJ, et al. Cerebral perfusion, electrical activity and effects of serotonergic treatment in obsessive-compulsive disorder: a preliminary study. Neuropsychobiology 1995; 32 (3): 139-48
25. 25. Swedo SE, Pietrini P, Leonard HL, et al. Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder: revisualization during pharmacotherapy. Arch Gen Psychiatry 1992 Sep; 49: 690-4
26. 26. Hoehn-Saric R, Pearlson GD, Harris GJ, et al. Effects of fluoxetine on regional cerebral blood flow in obsessive-compulsive patients. Am J Psychiatry 1991 Sep; 148: 1243-5
27. 27. Sherwood N. Comparative behavioural toxicity of the selective serotonin reuptake inhibitors. Hum Psychopharm 1995 Oct; 10 Suppl. 3: S159-162
28. 28. Hindmarch I. The behavioural toxicity of the selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 1995 Jan; 9 Suppl. 4: 13-7
29. 29. Ramaekers JG, Muntjewerff ND, O'Hanlon JF. A comparative study of acute and subchronic effects of dothiepin, fluoxetine and placebo on psychomotor and actual driving performance. Br J Clin Pharmacol 1995 Apr; 39: 397-404
30. 30. Gelfin Y, Gorfine M, Lerer B. Effect of clinical doses of fluoxetine on psychological variables in healthy volunteers. Am J Psychiatry 1998 Feb; 155: 290-2
31. 31. Alderman CP, Seshadri P, Bon-Tovim DI. Effects of serotonin reuptake inhibitors on haemostasis. Ann Pharmacother 1996 Nov; 30: 1232-4
32. 32. Berk M, Jacobson BF, Hurly E. Fluoxetine and hemostatic function: a pilot study. J Clin Psychiatry 1995 Jan; 56: 14-6
33. 33. Bondurant T, Darrell MJ, El Asyouty S, et al. Effect of fluoxetine on prothrombin time. Psychosomatics 1998 May-Jun; 39: 296-8
34. 34. Lainé-Cessac P, Shoaay I, Garre J-B, et al. Study of haemostasis in depressive patients treated with fluoxetine. Pharmacoepidemiol Drug Saf 1998 Aug; 7 Suppl. 1 : S54-7
35. 35. Foltin RW, Haney M, Comer SD, et al. Effect of fluoxetine on food intake of humans living in a residential laboratory. Appetite 1996 Oct; 27: 165-81
36. 36. Bross R, Hoffer LJ. Fluoxetine increases resting energy expenditure and basal body temperature in humans. Am J Clin Nutr 1995 May; 61: 1020-5
37. 37. Urdaneta E, Idoate I, Larralde J. Drug-nutrient interactions: inhibition of amino acid intestinal absorption by fluoxetine. Br J Nutr 1998 May; 79: 439-46
38. 38. Altamura AC, Moro AR, Percudani M. Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet 1994 Mar; 26: 201-14
39. 39. Goodnick PJ. Pharmacokinetics of second generation antidepressants: fluoxetine. Psychopharmacol Bull 1991; 27 (4): 503-12
40. 40. Catterson ML, Preskorn SH. Pharmacokinetics of selective serotonin reuptake inhibitors: clinical relevance. Pharmacol Toxicol 1996 Apr; 78: 203-8
41. 41. Preskorn S. Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. Int Clin Psychopharmacol 1994 Jun; 9 Suppl. 3: 13-9
42. 42. Palmer KJ, Benfield P. Fluvoxamine: an overview of its pharmacological properties and review of its therapeutic potential in non-depressive disorders. CNS Drugs 1994 Jan; 1 (1): 57-87
43. 43. Prakash A, Foster RH. Paroxetine: a review of its use in social anxiety disorder. CNS Drugs 1999 Aug; 12: 151-69
44. 44. Noble S, Benfield P. Citalopram: a review of its pharmacology, clinical efficacy and tolerability in the treatment of depression. CNS Drugs 1997 Nov; 8 (5): 410-31
45. 45. Perry CM, Benfield P. Sertraline: an overview of its pharmacological properties and a review of its therapeutic efficacy in obsessive-compulsive disorder. CNS Drugs 1997 Jun; 7: 480-500
46. 46. Lemberger L, Bergstrom RF, Wolen RL, et al. Fluoxetine: clinical pharmacology and physiologic disposition. J Clin Psychiatry 1985; 46 (3 Pt 2) Mar: 14-9
47. 47. von Moltke LL, Greenblatt DJ, Duan SX, et al. Human cytochromes mediating N-demethylation of fluoxetine in vitro [abstract]. Psychopharmacology 1997 Mar 5; 132: 402-7
48. 48. Verbesselt R, Tjandra-Maga TB, De Schepper PJ. Identification of cytochrome P450 isoforms involved in fluoxetine N-demethylation by C-DNA expressed enzymes [abstract]. Naunyn Schmiedebergs Arch Pharmacol 1998; 358 (1 Suppl. 2): 425
49. 49. Hamelin BA, Turgeon J, Vallée F, et al. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin Pharmacol Ther 1996 Nov; 60: 512-21
50. 50. DeVane CL. Translational pharmacokinetics: current issues with newer antidepressants. Depression Anxiety 1998; 8 Suppl. 1: 64-70
51. 51. Schenker S, Bergstrom RF, Wolen RL, et al. Fluoxetine disposition and elimination in cirrhosis. Clin Pharmacol Ther 1988; 44: 353-9
52. 52. Levy NB, Blumenfield M, Beasley Jr CM, et al. Fluoxetine in depressed patients with renal failure and in depressed patients with normal kidney function. Gen Hosp Psychiatry 1996 Jan; 18: 8-13
53. 53. Bergstrom RF, Farid KZ, McClurg JE, et al. The pharmacokinetics of fluoxetine in elderly subjects [abstract no. 699]. II World Conference on Clinical Pharmacology and Therapeutics; 1983 Jul 31-Aug 5: Washington
54. 54. Preskorn S, Shad M, Alderman J, et al. Fluoxetine: age and dose dependent pharmacokinetics and CYP 2C19 inhibition [abstract]. Clin Pharmacol Ther 1998 Feb; 63: 166
55. 55. Kristensen JH, Ilett KF, Hackett LP, et al. Distribution and excretion of fluoxetine and norfluoxetine in human milk [abstract]. Ther Drug Monit 1999 Aug; 21: 475
56. 56. Taddio A, Ito S, Koren G. Excretion of fluoxetine and its metabolite, norfluoxetine, in human breast milk. J Clin Pharmacol 1996 Jan; 36: 42-7
57. 57. Chambers CD, Johnson KA, Dick LM, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996 Oct 3; 335: 1010-5
58. 58. Koren G, Nulman I, Addis A. Outcome of children exposed in utero to fluoxetine: a critical review. Depression Anxiety 1998; 8 Suppl. 1: 27-31
59. 59. Aranow RB, Hudson JI, Pope Jr HG, et al. Elevated antidepressant plasma levels after addition of fluoxetine. Am J Psychiatry 1989 Jul; 146 (7): 790-2
60. 60. Goff DC, Midha KK, Brotman AW, et al. Elevation of plasma concentrations of haloperidol after the addition of fluoxetine. Am J Psychiatry 1991 Jun; 148 (6): 790-2
61. 61. Leonard BE. SSRI differentiation: pharmacology and pharmacokinetics. Hum Psychopharm 1995 Oct; 10 Suppl. 3: S149-58
62. 62. Mosby's GenRx: the complete reference for generic and brand drugs. 9th ed. Mosby-Year Book, Inc., 1999
63. 63. Shad MU, Preskorn SH. Drug-drug interaction in reverse: possible loss of phenytoin efficacy as a result of fluoxetine discontinuation. J Clin Psychopharmacol 1999 Oct; 19: 471-2
64. 64. Lemberger L, Rowe H, Bosomworth JC, et al. The effect of fluoxetine on the pharmacokinetics and psychomotor response of diazepam. Clin Pharmacol Ther 1988 Apr; 43 (4): 412-9
65. 65. Greenblatt DJ, Preskorn SH, Cotreau MM, et al. Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther 1992 Nov; 52 (5): 479-86
66. 66. Stokes PE, Holtz A. Fluoxetine tenth anniversary update: the progress continues. Clin Ther 1997 Sep-Oct; 19: 1135-250
67. 67. Grimsley SR, Jann MW, Carter JG, et al. Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin Pharmacol Ther 1991 Jul; 50 (1): 10-5
68. 68. Van der Kolk BA, Dreyfuss D, Michaels M, et al. Fluoxetine in posttraumatic stress disorder. J Clin Psychiatry 1994 Dec; 55: 517-22
69. 69. American Psychiatric Association. Diagnostic and statistical manual of mental disorders DSM-IV. 4th ed. Washington, D.C.: American Psychiatric Association, 1994
70. 70. Amore M, Magnani K, Cerisoli M. Short-term and long-term evaluation of selective serotonin reuptake inhibitors in the treatment of panic disorder: fluoxetine vs citalopram. Hum Psychopharm 1999 Aug; 14: 435-40
71. 71. Bystritsky A, Rosen RM, Murphy KJ, et al. Double-blind pilot trial of desipramine versus fluoxetine in panic patients. Anxiety 1994-95; 1: 287-90
72. 72. Amore M, Magnani K, Cerisoli M, et al. Panic disorder. A long-term treatment study: fluoxetine vs imipramine. Hum Psychopharm 1999 Aug; 14: 429-34
73. 73. Tiller JWG, Bouwer C, Behnke K. Moclobemide and fluoxetine for panic disorder. Eur Arch Psychiatry Clin Neurosci 1999; 249 Suppl. 1: S7-S10
74. 74. Michelson D, Lydiard RB, Pollack MH, et al. Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. Am J Psychiatry 1998 Nov; 155: 1570-7
75. 75. Michelson D, Pollack M, Lydiard RB, et al. Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine. Br J Psychiatry 1999 Mar; 174: 213-8
76. 76. Michelson D, Allgulander C, Sarkar N, et al. Fluoxetine in panic disorder: a randomized, placebo-controlled study. Lilly Research Laboratories, Indianapolis, 2000. (Data on file)
77. 77. Schneier FR, Liebowitz MR, Davies SO, et al. Fluoxetine in panic disorder. J Clin Psychopharmacol 1990 Apr; 10: 119-21
78. 78. Emmanuel NP, Ware MR, Brawman-Mintzer O, et al. Once-weekly dosing of fluoxetine in the maintenance of remission in panic disorder. J Clin Psychiatry 1999 May; 60: 299-301
79. 79. Pecknold JC, Luthe L, Iny L, et al. Fluoxetine in panic disorder: pharmacologic and tritiated platelet imipramine and paroxetine binding study. J Psychiatry Neurosci 1995 May; 20: 193-8
80. 80. Bocola V, Trecco MD, Fabbrini G, et al. Antipanic effect of fluoxetine measured by CO2 challenge test. Biol Psychiatry 1998 Apr 15; 43: 612-5
81. 81. Tiffon L, Coplan JD, Papp LA, et al. Augmentation strategies with tricyclic or fluoxetine treatment in seven partially responsive panic disorder patients. J Clin Psychiatry 1994 Feb; 55: 66-9
82. 82. Dannon PN, Hirschmann S, Kindler S, et al. Pindolol augmentation in the treatment of resistant panic disorder: a double-blind placebo-controlled trial [abstract]. Eur Neuropsychopharmacol 1997 Sep; 7 Suppl. 2: S231
83. 83. Fulton B, McTavish D. Fluoxetine: an overview of its pharmacodynamic and pharmacokinetic properties and review of its therapeutic efficacy in obsessive-compulsive disorder. CNS Drugs 1995 Apr; 3: 305-22
84. 84. Vertucci P, Bove RM, Scuccimarra G. Fluoxetine for treatment of obsessive compulsive disorders in adolescents. Preliminary data of an open study [abstract]. Eur Neuropsychopharmacol 1995 Sep; 5 Spec. issue: 372-3
85. 85. Baysal ZB, Ünal F. Fluoxetine treatment of children and adolescents with obsessive-compulsive disorders: a open-label trial [abstract]. Eur Neuropsychopharmacol 1996 Sep; 6 Suppl. 4: S4-142-3
86. 86. Eapen V, Trimble MR, Robertson MM. The use of fluoxetine in Gilles de la Tourelle syndrome and obsessive compulsive behaviours: preliminary clinical experience. Prog Neuropsych Biol Psychiatry 1996 May; 20: 737-43
87. 87. Koshes RJ. Use of fluoxetine for obsessive-compulsive behavior in adults wilh autism. Am J Psychiatry 1997 Apr; 154: 578
88. 88. Cook JEH, Terry EJ, Heller W, et al. Fluoxetine treatment of borderline mentally retarded adults with obsessive-compulsive disorder. J Clin Psychopharmacol 1990 Jun; 10: 228-9
89. 89. Montgomery SA, McIntyre A, Osterheider M, et al. A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. Eur Neuropsychopharmacol 1993 Jun; 3: 143-52
90. 90. Meszaros K, Zitterl W, Dossenbach M. A double-blind, placebo-controlled trial of fluoxetine in patients with obsessive-compulsive disorder in Austria [abstract]. Eur Neuropsychopharmacol 1995 Sep; 5 Spec. issue: 372
91. 91. Tollefson GD, Rampey Jr AH, Potvin JH, et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1994 Jul; 51: 559-67
92. 92. López-Ibor Jr JJ, Saiz J, Cottraux J, et al. Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder. Eur Neuropsychopharmacol 1996 May; 6: 111-8
93. 93. Greist JH, Jefferson JW, Kobak KA. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder: a meta analysis. Arch Gen Psychiatry 1995 Jan; 52: 53-60
94. 94. Stein DJ, Spadaccini E, Hollander E. Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder. Int Clin Psychopharmacol 1995 Mar; 10: 11-8
95. 95. Tollefson GD, Birkett M, Koran L. Continuation treatment of OCD: double-blind and open-label experience with fluoxetine. J Clin Psychiatry 1994 Oct; 55 Suppl.: 69-76
96. 96. Romano S, Goodman W, Tamura R. Long-term treatment of obsessive-compulsive disorder following acute response: a comparison of fluoxetine versus placebo [abstract]. Eur Neuropsychopharmacol 1998 Nov; 8 Suppl. 2: S261
97. 97. Frenkel A, Rosenthal J, Nezu A, et al. Efficacy of long-term fluoxetine treatment of obsessive-compulsive disorder. Mt Sinai J Med 1990 Nov; 57: 348-52
98. 98. Levine R, Hoffman JS, Knepple ED, et al. Long-term fluoxetine treatment of a large number of obsessive-compulsive patients. J Clin Psychopharmacol 1989 Aug; 9: 281-3
99. 99. Pigott TA, Pato MT, Bernstein SE, et al. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results. Arch Gen Psychiatry 1990 Oct; 47: 926-32
100. 100. Todorov C, Brassard M, Fontaine R, et al. Efficacy and tolerability of fluoxetine versus clomipramine in the treatment of obsessive-compulsive disorder [abstract]. Biol Psychiatry 1997 Jul 1; 42 Suppl.: 99S-100S
101. 101. Ananth J, Elmishad A, Wohl M. Clomipramine vs fluoxetine in obsessive-compulsive disorder: an uncontrolled study. Adv Ther 1993 Nov-Dec; 10: 288-92
102. 102. Cartwright C, Hollander E. SSRIs in the treatment of obsessive-compulsive disorder. Depression Anxiety 1998; 8 Suppl. 1: 105-13
103. 103. Greist JH. Treatment of obsessive-compulsive disorder: psychotherapies, drugs and other somatic treatment. J Clin Psychiatry 1990; 51 Suppl. 8: 44-50
104. 104. Judd F, Ellen S, Norman T, et al. Buspirone and fluoxetine in the treatment of OCD. Aust N Z J Psychiatry 1992 Dec; 26: 684-6
105. 105. Alessi N, Bos T. Buspirone augmentation of fluoxetine in a depressed child with obsessive-compulsive disorder. Am J Psychiatry 1991 Nov; 148: 1605-6
106. 106. Browne M, Horn E, Jones TT. The benefits of clomipramine-fluoxetine combination in obsessive compulsive disorder. Can J Psychiatry 1993 May; 38: 242-3
107. 107. Potenza MN, Wasylink S, Longhurst JG, et al. Olanzapine augmentation of fluoxetine in the treatment of refractory obsessive-compulsive disorder. J Clin Psychopharmacol 1998 Oct; 18: 423-4
108. 108. Koran L, Ringold A, Elliot M. Olanzapine added to fluoxetine in unresponsive obsessive-compulsive disorder [abstract]. Eur Neuropsychopharmacol 1999; 9 Suppl. 5: S305
109. 109. Cayetano JML, Essayag SM, Gonzalez G, et al. Use of risperidone for augmentation of SSRI's response in OCD. 11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, 217
110. 110. Connor KM, Sutherland SM, Tupler LA. Fluoxetine in post-traumatic stress disorder: randomised double-blind study. Br J Psychiatry 1999 Jul; 175: 17-22
111. 111. Nagy LM, Morgan III CA, Southwick SM, et al. Open prospective trial of fluoxetine for posttraumatic stress disorder. J Clin Psychopharmacol 1993 Apr; 13: 107-13
112. 112. McDougle CJ, Southwick SM, Charney DS, et al. An open trial of fluoxetine in the treatment of posttraumatic stress disorder. J Clin Psychopharmacol 1991 Oct; 11: 325-7
113. 113. De Clercq M, Hoyois PH, Vermeiren E. Open-label study of fluoxetine in civilian post-traumatic stress disorder [abstract]. Eur Neuropsychopharmacol 1999 Sep; 9 Suppl. 5: S221
114. 114. Wells BG, Cates M, de Cunha C, et al. An open trial of fluoxetine in treatment of post-traumatic stress disorder [abstract]. Psychopharmacol Bull 1995; 31 (3): 629
115. 115. Folnegovic Šmalc V, Folnegovic Z, Kocijan D, et al. Fluoxetine in therapy of persons with PTSD [abstract]. Eur Neuropsychopharmacol 1995 Sep; 5 Spec. issue: 312
116. 116. Folnegovic-Šmalcv V, Folnegovic Z, Kozaric-Kovacic D, et al. The treatment of acute posttraumatic stress disorder with fluoxetine [abstract]. Eur Neuropsychopharmacol 1996 Apr; 6 Suppl. 1: 24-5
117. 117. Folnegovic-Šmalc V, Folnegovic Z, Henigsberg N, et al. Efficacy of fluoxetine in PTSD patients [abstract]. Biol Psychiatry 1997 Jul 1; 42 Suppl.: 32
118. 118. Crnobaric C, Jašovic-Gašic M, Miljevic C. Effectiveness of drug therapy in social phobia. Eur Neuropsychopharmacol 1998 Mar; 8 Suppl. 1 : S25-6
119. 119. Ilies-Alexandru D, Zaharia C, Grigorescu A-M. Prozac versus anafranil in the therapy of social phobia and agoraphobia [abstract]. Eur Neuropsychopharmacol 1998 Mar; 8 Suppl. 1: S27
120. 120. Black B, Uhde TW, Tancer ME. Fluoxetine for the treatment of social phobia. J Clin Psychopharmacol 1992 Aug; 12: 293-5
121. 121. Perugi G, Nassini S, Lenzi M, et al. Treatment of social phobia with fluoxetine. Anxiety 1994-95; 1: 282-6
122. 122. Schneier FR, Chin SJ, Hollander E, et al. Fluoxetine in social phobia [letter]. J Clin Psychopharmacol 1992 Feb; 12: 62-4
123. 123. Carrasco JL, Hollander E, Schneier FR, et al. Treatment outcome of obsessive compulsive disorder with comorbid social phobia. J Clin Psychiatry 1992 Nov; 53: 387-91
124. 124. Fawcett J. The detection and consequences of anxiety in clinical depression. J Clin Psychiatry 1997; 58 Suppl. 8: 35-40
125. 125. Keller MB, Hanks DL. Anxiety symptom relief in depression treatment outcomes. J Clin Psychiatry 1995; 56 Suppl. 6: 22-9
126. 126. Montgomery SA, Judge RJ. Treatment of depression with associated anxiety: comparisons of tricyclic antidepressants and selective serotonin reuptake inhibitors. Proceedings of a consensus meeting held in Geneva, Switzerland, Oct 5-6, 1998 (Data on file)
127. 127. Bakish D, Habib R, Hooper CL. Mixed anxiety and depression: diagnosis and treatment options. CNS Drugs 1998 Apr; 9: 271-80
128. 128. Zinbarg RE, Barlow DH, Liebowitz M, et al. The DSM-IV field trial for mixed anxiety-depression. Am J Psychiatry 1994 Aug; 151 (8): 1153-62
129. 129. Van Valkenburg C, Akiskal HS, Puzantian V, et al. Anxious depressions: clinical, family history, and naturalistic outcome - comparisons with panic and major depressive disorders. J Affect Disord 1984; 6: 67-82
130. 130. Emmanuel J, Simmonds S, Tyrer P. Systematic review of the outcome of anxiety and depressive disorders. Br J Psychiatry 1998; 173 suppl. 34: 35-41
131. 131. Tollefson GD, Greist JH, Jefferson JW, et al. Is baseline agitation a relative contraindication for a selective serotonin reuptake inhibitor: a comparative trial of fluoxetine versus imipramine. J Clin Psychopharmacol 1994 Dec; 14: 385-91
132. 132. Marchesi C, Ceccherininelli A, Rossi A, et al. Is anxious-agitated major depression responsive to fluoxetine? A double-blind comparison with amitriptyline. Pharmacopsychiatry 1998 Nov; 31: 216-21
133. 133. Versiani M, Plewes J, Ontiveiros A, et al. Fluoxetine and amitriptyline in the treatment of major depression with associated anxiety [abstract]. Eur Neuropsychopharmacol 1998; 8 Suppl. 2: S187
134. 134. Geerts S, Lacante P, Mignon A. Venlafaxine versus fluoxetine in the treatment of depressed patients with concomitant anxiety [abstract]. Eur Neuropsychopharmacol 1999; 9 Suppl. 5: S224
135. 135. Silverstone PH, Ravindran A, Venlafaxine XR 360 Study Group. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. J Clin Psychiatry 1999 Jan; 60: 22-8
136. 136. Tollefson GD, Holman SL, Sayler ME. Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. J Clin Psychiatry 1994 Feb; 55: 50-9
137. 137. Fava M, Rosenbaum JF, Hoog SL, et al. Fluoxetine versus sertaline and paroxetine in major depression: efficacy and tolerability in patients with high or low baseline anxiety [abstract no. P.1.054]. Eur Neuropsychopharmacol 1998 Nov; 8 Suppl. 2: S152
138. 138. Fava M, Rosenbaum JF, Hoog S, et al. Fluoxetine versus sertraline and paroxetine in major depression: safety and efficacy in anxious and nonanxious subgroups [abstract]. Biol Psychiatry 1998 Apr 15; 43 Suppl.: 103S
139. 139. Geerts S, Mignon A, Lacante P. Venlafaxine versus fluoxetine in the treatment of depression with anxiety [abstract]. 11th World Congress of Psychiatry; 1999 Aug 6-11 ; Hamburg, 206-7
140. 140. Mackay FJ, Dunn NR, Wilton LV, et al. A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies. Pharmacoepidemiol Drug Saf 1997 Jul-Aug; 6: 235-46
141. 141. Rudorfer MV, Manji HK, Potter WZ. Comparative tolerability profiles of the newer versus older antidepressants. Drug Saf 1994; 10 (1): 18-46
142. 142. Devane CL. Comparative safety and tolerability of selective serotonin reuptake inhibitors. Hum Psychopharm 1995 Oct; 10 Suppl. 3: S185-93
143. 143. Spigset O. Adverse reactions of selective serotonin reuptake inhibitors: reports from a spontaneous reporting system. Drug Saf 1999 Mar; 20: 277-87
144. 144. Price JS, Waller PC, Wood SM, et al. A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol 1996 Dec; 42: 757-63
145. 145. Edwards JG, Inman WHW, Wilton L, et al. Drug safety monitoring of 12 692 patients treated with fluoxetine. Hum Psychopharm 1997 Mar-Apr; 12: 127-37
146. 146. Pande AC, Sayler ME. Adverse events and treatment discontinuations in fluoxetine clinical trials. Int Clin Psychopharmacol 1993; 8 (4): 267-9
147. 147. Zajecka J, Amsterdam JD, Quitkin FM, et al. Changes in adverse events reported by patients during 6 months of fluoxetine therapy. J Clin Psychiatry 1999 Jun; 60: 389-94
148. 148. Michelson D, Amsterdam JD, Quitkin FM, et al. Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry 1999 Aug; 156: 1170-6
149. 149. Aldrich AP, Cook MD, Pedersen LR. Retrospective review of selective serotonin reuptake inhibitor-induced libido disturbance in women. Clin Drug Invest 1996 Jun; 11: 353-9
150. 150. Shen WW, Hsu JH. Female sexual side effects associated with selective serotonin reuptake inhibitors: a descriptive clinical study of 33 patients. Int J Psychiatry Med 1995; 25 (3): 239-48
151. 151. Hsu JH, Shen WW. Male sexual side effects associated with antidepressants: a descriptive clinical study of 32 patients. Int J Psychiatry Med 1995; 25 (2): 191-201
152. 152. Zajecka J, Fawcett J, Schaff M, et al. The role of serotonin in sexual dysfunction: fluoxetine-associated orgasm dysfunction. J Clin Psychiatry 1991; 52: 66-8
153. 153. Patterson WM. Fluoxetine-induced sexual dysfunction [letter]. J Clin Psychiatry 1993 Feb; 54: 71
154. 154. Michelson D, Schmidt M, Johnston R, et al. Sexual functioning during acute and continuation therapy with fluoxetine: a prospective assessment. Lilly Research Laboratories, Indiana, 2000. (Data on file)
155. 155. Modell JG, Katholi CR, Modell JD, et al. Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline. Clin Pharmacol Ther 1997 Apr; 61: 476-87
156. 156. Montejo AL, Llorca G, Izquierdo JA. Antidepressant-induced sexual dysfunction: a multicenter and prospective study using a questionnaire of 693 patients [abstract no. NR658]. American Psychiatric Association 1999 Annual Meeting; 1999 May 15-20; Washington DC, 254
157. 157. Healy D. The fluoxetine and suicide controversy: a review of the evidence. CNS Drugs 1994 Mar; 1 (3): 223-31
158. 158. Jick SS, Dean AD, Jick H. Antidepressants and suicide. BMJ 1995 Jan 28; 310: 215-8
159. 159. Beasley Jr CM, Potvin JH, Masica DN, et al. Fluoxetine: no association with suicidality in obsessive-compulsive disorder. J Affect Disord 1992 Jan; 24: 1-10
160. 160. Leon AC, Keller MB, Warshaw MG, et al. Prospective study of fluoxetine treatment and suicidal behavior in affectively ill subjects. Am J Psychiatry 1999 Feb; 156: 195-201
161. 161. Warshaw MG, Keller MB. The relationship between fluoxetine use and suicidal behavior in 654 subjects with anxiety disorders. J Clin Psychiatry 1996 Apr; 57: 158-66
162. 162. ABPI compendium of data sheets and summaries of product characteristics; with the code of practice for the pharmaceutical industry. London: Datapharm Publications Limited, 1998
163. 163. Lejoyeux M, Adès J, Rouillon F. Serotonin syndrome: incidence, symptoms and treatment. CNS Drugs 1994 Aug; 2: 132-43
164. 164. Berlin CS. Fluoxetine withdrawal syndrome. J Clin Psychiatry 1996 Feb; 57: 93-4
165. 165. Stahl MMS, Lindquist M, Pettersson M, et al. Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system. Eur J Clin Pharmacol 1997 Nov-Dec; 53: 163-9
166. 166. Therrien F, Markowitz JS. Selective serotonin reuptake inhibitors and withdrawal symptoms: a review of the literature. Hum Psychopharm 1997 Jul-Aug; 12: 309-23
167. 167. Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998 Jul 15; 44: 77-87
168. 168. Michelson D, Fava M, Amsterdam J, et al. Interruption of selective serotonin reuptake inhibitor treatment. Br J Psychiatry 2000; 176: 363-8
169. 169. Steiner W. Fluoxetine-induced mania in a patient with obsessive-compulsive disorder [letter]. Am J Psychiatry 1991 Oct; 148: 1403-4
170. 170. Levy D, Kimhi R, Barak Y, et al. Antidepressant-associated mania: a study of anxiety disorders patients. Psychopharmacology 1998 Apr; 136: 243-6
171. 171. Go FS, Malley EE, Birmaher B. Manic behaviors associated with fluoxetine in three 12-to 18-year-olds with obsessive-compulsive-disorder. J Child Adolesc Psychopharmacol 1998; 8 (1): 73-80
172. 172. Fux M, Taub M, Zohar J. Emergence of depressive symptoms during treatment for panic disorder with specific 5-hydroxytryptophan reuptake inhibitors. Acta Psychiatr Scand 1993 Oct; 88: 235-7
173. 173. Swartz CM, Guadagno G. Melancholia with onset during treatment with SSRIs. Ann Clin Psychiatry 1998 Dec; 10: 177-9
174. 174. Fava GA. Potential sensitising effects of antidepressant drugs on depression. CNS Drugs 1999 Oct; 12 (4): 247-56
175. 175. Prozac: fluoxetine hydrochloride. Eli Lilly and Company, August 11, 1999; Indianapolis. (Data on file)
176. 176. Fava GA, Mangelli L. Subclinical symptoms of panic disorder: new insights into pathophysiology and treatment. Psychother Psychosom 1999; 68 (6): 281-9
177. 177. Sheehan DV. Current concepts in the treatment of panic disorder. J Clin Psychiatry 1999; 60 Suppl. 18: 16-21
178. 178. Gorman JM, Coplan JD. Comorbidity of depression and panic disorder. J Clin Psychiatry 1996; 57 Suppl. 10: 34-41
179. 179. Sheehan DV, Harnett-Sheehan K. The role of SSRIs in panic disorder. J Clin Psychiatry 1996; 57 Suppl. 10: 51-8
180. 180. Goddard AW, Charney DS. SSRIs in the treatment of panic disorder. Depression Anxiety 1998; 8 Suppl. 1: 114-20
181. 181. Treatment of obsessive-compulsive disorder. J Clin Psychiatry 1997; 58 Suppl. 4: 1-72
182. 182. Ravizza L, Maina G, Bogetto F, et al. Long term treatment of obsessive-compulsive disorder. CNS Drugs 1998 Oct; 10: 247-55
183. 183. Dominguez RA, Mestre SM. Management of treatment-refractory obsessive compulsive disorder patients. J Clin Psychiatry 1994 Oct; 55 Suppl.: 86-92
184. 184. Expert Consensus Panels for PTSD. Treatment of posttraumatic stress disorder. J Clin Psychiatry 1999; 60 Suppl. 16: 1-76
185. 185. Ballenger JC, Davidson JRT, Lecrubier Y, et al. Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 1998; 59 Suppl. 17: 54-60
186. 186. Tollefson GD, Sayler ME. Course of psychomotor agitation during pharmacotherapy of depression: analysis from double-blind controlled trials with fluoxetine. Depression Anxiety 1996-1997; 4 (6): 294-311
187. 187. Lane R, Baldwin D, Preskorn S. The SSRIs: advantages, disadvantages and differences. J Psychopharmacol 1995; 9 (2) Suppl.: 163-78
188. 188. Finley PR. Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions. Ann Pharmacother 1994 Dec; 28: 1359-69
189. 189. Van Den Berg SJ Comparing SSRIs: from chemistry to clinical choice. Hum Psychopharm 1995 Oct; 10 Suppl. 3: S199-209